PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive
|
|
- Dylan Gilmore
- 6 years ago
- Views:
Transcription
1 Prostate-Specific Antigen Doubling Times Are Similar in Patients With Recurrence After Radical Prostatectomy or Radiotherapy: A Novel Analysis By Bryan D. Leibman, Ozdal Dillioglugil, Peter T. Scardino, Farhat Abbas, Eamonn Rogers, Russell D. Wolfinger, and Michael W. Kattan Purpose: Some investigators have analyzed the rate of growth of prostate cancer that has recurred after definitive radiotherapy or radical prostatectomy using serum prostate-specific antigen (PSA) doubling times (DT). We examined all PSA values in recurrent patients to determine the pattern and rate of increase in PSA after radiation therapy and radical prostatectomy. Patients and Methods: Charts of 9 recurrent radical prostatectomy patients (mean age, 2.8 years; range, 47 to 7) and 42 recurrent radiation therapy patients (mean age, 7.2 years; range, 52 to 83) were reviewed. All available PSA values between the date of operation/radiation treatment and last follow-up evaluation or the initiation of second-line therapy are included. Rate of PSA DT was not assumed to be constant over time; it was instead allowed to vary. We use a piecewise linear random-coefficients model in time for log(psa), which allowed different mean models for both treatments. Results: The PSA DT in the first year after radiation therapy was years, which reflects the continuous decline in PSA in the average patient during the first year after radiotherapy despite eventual biochemical progression. In contrast, the PSA DT in the radical prostatectomy group was 0. in the first year. In year 2, after radiation therapy, the PSA DT was lengthy at 1.82 years, significantly longer (P =.0025) than in the radical prostatectomy group (0.7 years). After year 2, there were no significant differences between the two groups (P >.05). Conclusion: A piecewise linear random-coefficients model enables interval analysis of PSA DT. While the PSA DT after radiation therapy and radical prostatectomy are different in the first 2 years, the rate of increase in PSA appears to be similar in the two groups after year 2, which suggests the rate of growth of cancers that recur after radiation therapy and radical prostatectomy is similar. J Clin Oncol 1: by American Society of Clinical Oncology. PROSTATE-SPECIFIC ANTIGEN (PSA) is a sensitive marker of the response of prostate cancer to definitive therapy with either radical prostatectomy or radiation therapy. Stamey et all reported PSA levels correlate with tumor volume. PSA doubling times (DTs) should therefore estimate tumor doubling times. Previous studies have examined PSA DT after radical prostatectomy 2, 3 and radiation therapy. 4-7 They found a strong association between PSA DT and pretreatment PSA level, biopsy Gleason sum, and ploidy status. 5 Also, faster DTs have been associated with aggressive tumor biology 7 and have assisted in predicting distant versus local recurrence. 2 PSA DT can thus be used to predict site of recurrence and to estimate tumor volume, and has been shown to be a strong prognostic factor for patients with biochemical evidence of progression after radiotherapy or radical prostatectomy. 2 On the other hand, an isolated PSA elevation doeý not help to distinguish local recurrence, which might benefit from irradiation to the prostatic bed, from distant metastasis that needs hormonal therapy. In this study, we compare PSA DTs for patients with recurrent disease after either radiation therapy or radical prostatectomy. Unlike previous studies, we do not assume PSA DT to be constant over time. We present a statistical model to analyze PSA DT at selected intervals, allowing variation in the event that the DT is not constant. PATIENTS AND METHODS All patients with clinically localized prostate cancer (ct1-3nxmo) initially seen in consultation in the Department of Urology who were treated with intent to cure with either definitive radiation therapy or radical prostatectomy at our hospital between June 1983 and August 1994, and who were subsequently monitored in our Urology Department (radiation therapy, n = 9; radical prostatectomy, n = 1,17), were reviewed to identify those with evidence of progression after treatment. Clinical stage distribution according to the 1992 tumor-nodemetastasis (TNM) classification system 8 for the 1,23 men in this study was as follows: Tla, 4%; Tlb, %; Tlc, 12%; T2a, 21%; T2b, 27%; T2c, 23%; T3a, %; T3b, 0.1%; and T3c, 1%. From the Matsunaga-Conte Prostate Cancer Research Center, Scott Department of Urology, and Information Technology Program, Baylor College ofmedicine, Houston, TX; and SAS Institute, Inc, Cary, NC. Submitted September 25, 1997; accepted March 1, Supported in part by Specialized Program of Research Excellence (SPORE) grant no. CA58204 from the National Cancer Institute, Bethesda, MD. Address reprint requests to Michael W. Kattan, PhD, Scott Department of Urology, Baylor College of Medicine, 535 Fannin St, F 403, Houston, TX 77030; mkattan@bcm.tmc.edu by American Society of Clinical Oncology X/98/ $3.00/0 Journal of Clinical Oncology, Vol 1, No (June), 1998: pp
2 228 LEIBMAN ET AL Table 1. Distribution of Clinical Stage by Treatment Group: Radical Prostatectomy Versus Radiation Therapy Clinical Radical Prostatectomy Group Radiation Therapy Group Stage No. % No. % Tla Tlb Tic T2a T2b T2c T3a T3b T3c NOTE. Radiation therapy patients had a higher clinical stage at presentation. Sixty percent of the radiation therapy patients had a T3 tumor v 12% in the radical prostatectomy group. Wilcoxon rank-sum, P <.001. There were 42 patients with disease progression by PSA parameter after either external-beam irradiation therapy alone (n = 34) or brachytherapy (interstitial radioactive gold-198 seed implantation) plus externalbeam therapy (n = 8).9 Treatment was directed to the prostate only, except in patients with proven pelvic lymph node metastases. There were 9 patients who progressed according to PSA after radical retropubic or radical perineal prostatectomy. Pretreatment clinical stage (International Union Against Cancer [UICC] criteria), PSA, and biopsy Gleason sum are listed in Tables 1, 2, and 3. The Wilcoxon rank-sum test was used to compare these parameters across treatments. Clinical stage was prospectively recorded according to the TNM classification system, although men treated before 1992 were retrospectively reassigned from the equivalent Whitmore-Jewett stages. 15 The mean follow-up duration for radical prostatectomy patients was 33. months (range, 47 to 7), and for radiation therapy patients, 49.4 months (range, 5 to 139). Serum PSA level was determined by the Hybritech assay (Hybritech Tandem-R; Hybritech, San Diego, CA). After radical prostatectomy, progression according to PSA was defined as a PSA measurement > 0.4 ng/ml and increasing on at least one subsequent measurement. For radiation therapy, progression according to PSA was defined as a PSA measurement > 1 ng/ml and increasing after a nadir was achieved. All patients in this study had an elevated PSA value as the first evidence of recurrence. All available PSA values between the date of treatment and last follow-up evaluation Table 2. Distribution of Preoperative Biopsy Gleason Sum by Treatment Group: Radical Prostatectomy Versus Radiation Therapy Biopsy Radical Prostatectomy Group Radiation Therapy Group Gleason Sum No. % No. % Total Wilcoxon rank-sum P =.43 Mean.3.0 Median Range NOTE. Both treatment groups were similar in terms of biopsy Gleason sum. Table 3. Distribution of Preoperative PSA by Treatment Group: Radical Prostatectomy Versus Radiation Therapy Preoperative Radical Prostatectomy Group Radiation Therapy Group PSA (ng/ml) No. % No. % > > 4-s > > > Total Wilcoxon rank-sum P =.80 Mean Median Range NOTE. Both treatment groups were similar in terms of preoperative PSA. or the initiation of second-line therapy were included. Eighty-five percent of patients in the radical prostatectomy group and 90% of those in the radiation therapy group had at least four posttreatment PSA measurements, while 4% and 1%, respectively, had at least seven measurements (Table 4). Rate of PSA DT was not assumed to be constant during the follow-up period after definitive therapy. Instead, it was allowed to vary over time and was analyzed at yearly intervals. We are using a piecewise linear random coefficients model in time for log(psa), allowing different mean models for the two treatments. The log transformation is used because of the scale of the measurements and because a likelihoodbased comparison of several transformations in the Box-Cox family indicated log as the best. Because the measurements are unequally spaced and from a preliminary graphical analysis of the data, the join points for the piecewise linear mean model are selected to be at 1, 2, 3, and 7 years. The transformed data for each patient are assumed to follow a Gaussian distribution with a mean following the aforementioned piecewise linear form and variance-covariance matrix derived as follows. Each patient is assumed to possess a random intercept, a random slope for 0 to 1 years, and a random slope for 1 to 2 years, in addition to the standard residual error. The three random coefficients are added to the mean model and are assumed to have a Gaussian distribution with mean zero and an unstructured covariance matrix. The additive residual error is also assumed to have a Gaussian distribution with mean zero and unknown variance, and is independent of the random coefficients. Each patient is assumed to follow the same model Table 4. Distribution of the Total Number of PSA Measurements After Radical Prostatectomy and Radiation Therapy No. of PSA Radical Prostatectomy Radiation Therapy Measurements No. % No. % > NOTE. Eighty-five percent of patients in the radical prostatectomy group and 90% of patients in the radiation therapy group had at least 4 posttreatment PSA measurements.
3 PSA DOUBLING TIMES (but with different realizations of the random variables), and data from different patients are assumed to be independent." The random coefficients model provides an appealing way to handle within-subject correlations. Our particular model was selected as best among models that have zero, one, two or more than three random coefficients, using restricted likelihood versions of Akaike's and Schwarz's criteria as guides." It also fits much better than an unequally spaced First-Order Autoregressive (AR[1]) model and the model that adds an unequally spaced AR(1) covariance matrix to the one generated by the random coefficients,12 both according to the same criteria. RESULTS Radiation therapy patients had higher clinical stage at presentation compared with radical prostatectomy patients (P =.001). Sixty percent of the radiation therapy group had a T3 tumor, compared with 12% in the radical prostatectomy group. Eighty percent of the radical prostatectomy patients were clinical stage T2, compared with 31% of the radiation therapy patients (Table 2). Distribution of pretreatment biopsy Gleason sum was similar in the two groups (P =.43). Mean Gleason sum in the radical prostatectomy patients was.3 and in the radiation therapy patients,.0. Median Gleason sum was 7 and, respectively (Table 3). Pretreatment PSA distribution was also similar between the two groups (P =.80) (Table 4). In the first year after radiotherapy, the PSA DT was years. The negative value reflects the continuing decline in PSA in most patients during the first year after radiotherapy despite eventual biochemical progression. In contrast, the PSA DT was 0. in the first year after radical prostatectomy. In year 2, after radiotherapy, the PSA DT was long, at 1.82 years, which was significantly longer (P =.0025) than the PSA DT after radical prostatectomy (0.7 years). After year 2, there were no significant differences between the two groups (P >.05) (Table 5 and Fig 1). DISCUSSION PSA is an antigen first described by Wang et al.13 It is a glycoprotein with serine protease activity, found in the cytoplasm in both benign and malignant prostate cells. PSA represents the best serum marker for prostatic carcinoma, 229 and it has the highest validity of any circulating marker for cancer today. 14 PSA is extremely useful to monitor patients for recurrence after definitive therapy for prostate cancer. Increasing serum PSA levels precede clinical recurrence detected by traditional tests such as digital rectal examination (DRE), bone scan, or other radiologic studies by 3 to years. 15 PSA progression, or biochemical failure, is therefore the most rapid means to assess results of contemporary treatment. PSA levels have been shown to correlate with tumor volume.' Schmid et a1' demonstrated a linear relationship between serum PSA levels and cancer volume. On average, one gram of cancer was shown to produce an increase in PSA of 3.5 ng/ml. The investigators therefore proposed that serial PSA determinations in the absence of any therapy should reflect the DT of the prostate cancer. They also showed that the increase in PSA in untreated patients was exponential and the DTs occurred more rapidly with higher disease stage and grade. It is not clear when to initiate additional treatment for patients with evidence of biochemical failure after radical prostatectomy or radiation therapy. Numerous factors are usually considered in this decision-making process; these include histologic grade, pathologic stage, pretreatment PSA level, time from treatment, clinical symptoms, physical findings, and radiologic abnormalities. Several studies have also touted the benefit of PSA DT in aiding in this process. 2-7 For patients with recurrent disease after radiation therapy, a short PSA DT has been shown to be associated with poorly differentiated cancers, nondiploid DNA profile, and an increased chance of distant metastasis. Zagars and Pollock 5 also noted that a faster PSA DT in radiorecurrent patients correlated significantly with high pretreatment Gleason sum and PSA level. D'Amico and Hanks 7 found a short DT correlated with the interval to clinical relapse, which suggested the potential usefulness of PSA DT to identify patients who might benefit from early second-line treatment. Pollack et al, in a linear regression analysis of PSA DT and disease relapse after radiotherapy, found a significant corre- Table 5. PSA DT by Treatment Group Year Group PSA DT 95% CI PSA DT 95% CI PSA DT 95% CI PSA DT 95% CI Radical prostatectomy Radiation therapy (-).93-(-) oo P NOTE. In the year immediately following radiation therapy, PSA DT was negative due to the PSA-lowering effect of radiation therapy. This resulted in a significant difference from the radical prostatectomy group. After year 2, there were no significant differences between the 2 groups. *Undefined.
4 2270 LEIBMAN ET AL L O G P S A Fig 1. Piecewise linear randomcoefficients model in time for log(psa) YEAR 7 -stimatea ppopulation curves are superinmposea lation, in which a PSA DT of 11 months predicted a disease relapse 24 months later. Their findings concur with others in suggesting that PSA DT is a strong prognostic factor for disease progression after definitive radiation therapy. After radical prostatectomy, serum PSA levels should become undetectable. For patients with biochemical evidence of failure after radical prostatectomy, important prognostic information can be gained from the relapse interval and PSA DT. With local recurrence, PSA first becomes detectable, on average, about 3 years later than with distant recurrence. 15 Most patients with an increasing PSA within the first year after surgery will manifest distant metastasis. Trapasso et a1 2 noted that the median PSA DT was 4.3 months for patients who progressed to distant metastasis, compared with 11.7 months for patients who had either clinical local recurrence or an isolated PSA elevation as sole indicator of recurrence. Stamey et al, 17 studied PSA DT in patients after radiation therapy and reported an accelerated growth rate in recurrent radiotherapy patients compared with untreated patients with prostate cancer; they suggested that this acceleration may result from tumor clonogen repopulation during radiotherapy. We examined PSA DT in recurrent patients after both radiation therapy and radical prostatectomy for comparison purposes. These two groups of patients are similar before definitive therapy when comparing biopsy Gleason sum and pretreatment PSA level. However, patients in the radiation therapy group had a higher pretreatment clinical stage. Our study analyzes PSA DT at yearly intervals and does not assume PSA DT to be constant over time. This represents a novel method to calculate PSA DT. We found PSA DT to be negative in the first year after radiation therapy in contrast to the radical prostatectomy group; this is consistent with the fact that radiation therapy is known and expected to produce declining PSA levels after treatment. Serum PSA declined and reached a nadir in the first year after radiation therapy, with a subsequent increase. PSA began to increase slowly in the radiation therapy group during the second year, but the rate was slower than that for the radical prostatectomy group in the second year (P <.05). After year 2, there were no significant differences in PSA DT for patients after radiation therapy or radical prostatectomy. This finding is consistent with data reported by Fowler et al,18 who compared PSA DT by linear regression analysis in recurrent patients after radical prostatectomy and radiation therapy. They found no significant differences between these groups, which suggests the malignant potentials of recurrent tumor after either of these therapeutic modalities are equivalent. Our results, like those of Fowler et al, differ from the earlier work reported by Stamey et al. 1 7 We believe Stamey's assumptions may be too strong. Patients who fail to respond to definitive local therapy cannot be presumed to have similar cancer characteristics as
5 PSA DOUBLING TIMES all patients initially diagnosed with prostate cancer. Also, they are clearly different than a group of patients with clinically organ confined prostate cancer who have elected or been selected to have no definitive treatment. Patients most commonly fail to respond to definitive therapy because they have occult metastases before treatment. When these patients fail to respond, their PSA DT will be similar to patients with known early metastatic disease. Other patients fail to respond because of local recurrence, and the more rapidly growing (poorly differentiated) cancers that recur will 2271 become apparent sooner. We know that PSA DT is shorter for patients with high-grade cancer.'" In patients monitored for the first years after definitive radiotherapy or radical prostatectomy, the detected recurrences will naturally have a PSA DT reflective of early metastatic prostate cancer or high-grade rapidly growing local tumor. Consequently, the shorter PSA DT in patients who fail to respond to radical prostatectomy or radiation therapy, when compared with untreated patients, is more likely to represent selection factors, rather than a changing biology of the tumor. 1. Stamey TA, Kabalin JN, McNeal JE, et al: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141: , Trapasso JG, dekemion JB, Smith RB, et al: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152: , Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:49-59, Hanks GE, D'Amico A, Epstein BE, et al: Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys 27: , Zagars GK, Pollack AP: Radiation therapy for T1 and T2 prostate cancer: Prostate-specific antigen and disease outcome. Urology 45:47-483, Pollack AP, Zagars GK, Kavadi VS: Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74:70-78, D'Amico AV, Hanks GE: Linear regressive analysis using prostatespecific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72: , Beahrs OH, Henson DE, Hutter RV, et al (eds): Manual for Staging of Cancer. Philadelphia, PA, Lippincott, Butler EB, Scardino PT, The BS, et al: The Baylor College of REFERENCES Medicine experience with gold seed implantation. Semin Surg Oncol 13:40-418, Ohori M, Wheeler TM, Scardino PT: The new American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer: Clinicopathologic correlations. Cancer 74: , Littell RC, Milliken GA, Stroup WW, et al: SAS System for Mixed Models. Cary, NC, SAS Institute, Diggle PJ, Liang KY, Zeger SL: Analysis of Longitudinal Data. Oxford, United Kingdom, Clarendon, Wang MC, Valenzuela LA, Murphy GP, et al: Purification of a human prostate specific antigen. Invest Urol 17:159-13, Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer. JAMA 273: , Frazier HA, Robertson JE, Humphrey PA, et al: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 149:51-518, Schmid H, McNeal JE, Stamey TA: Observations on the doubling time of prostate cancer. Cancer 71: , Stamey TA, Ferrari MK, Schmid H-P: The value of serial prostate specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol 150: , Fowler JE, Pandey P, Braswell NT, et al: Prostate specific antigen progression rates after radical prostatectomy or radiation for localized prostate cancer. Surgery 11:302-30, 1994
Outcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationCONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM
RAPID COMMUNICATION CME ARTICLE CONTEMPORARY UPDATE OF PROSTATE CANCER STAGING NOMOGRAMS (PARTIN TABLES) FOR THE NEW MILLENNIUM ALAN W. PARTIN, LESLIE A. MANGOLD, DANA M. LAMM, PATRICK C. WALSH, JONATHAN
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationInformation Content of Five Nomograms for Outcomes in Prostate Cancer
Anatomic Pathology / NOMOGRAMS IN PROSTATE CANCER Information Content of Five Nomograms for Outcomes in Prostate Cancer Tarek A. Bismar, MD, 1 Peter Humphrey, MD, 2 and Robin T. Vollmer, MD 3 Key Words:
More informationA NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY
ADULT UROLOGY CME ARTICLE A NEURAL NETWORK PREDICTS PROGRESSION FOR MEN WITH GLEASON SCORE 3 4 VERSUS 4 3 TUMORS AFTER RADICAL PROSTATECTOMY MISOP HAN, PETER B. SNOW, JONATHAN I. EPSTEIN, THERESA Y. CHAN,
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationEarly outcomes of active surveillance for localized prostate cancer
Original Article ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER HARDIE et al. Early outcomes of active surveillance for localized prostate cancer CLAIRE HARDIE, CHRIS PARKER, ANDREW NORMAN*, ROS EELES,
More informationDivision of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine, Durham, NC
LHRH AGONISTS: CONTEMPORARY ISSUES The Evolving Definition of Advanced Prostate Cancer Judd W. Moul, MD, FACS Division of Urologic Surgery and Duke Prostate Center (DPC), Duke University School of Medicine,
More informationThe Selenium and Vitamin E Prevention Trial
The largest-ever-prostate cancer prevention trial is now underway. The study will include a total of 32,400 men and is sponsored by the National Cancer Institute and a network of researchers known as the
More informationin 32%, T2c in 16% and T3 in 2% of patients.
BJUI Gleason 7 prostate cancer treated with lowdose-rate brachytherapy: lack of impact of primary Gleason pattern on biochemical failure Richard G. Stock, Joshua Berkowitz, Seth R. Blacksburg and Nelson
More informationPrognostic value of the Gleason score in prostate cancer
BJU International (22), 89, 538 542 Prognostic value of the Gleason score in prostate cancer L. EGEVAD, T. GRANFORS*, L. KARLBERG*, A. BERGH and P. STATTIN Department of Pathology and Cytology, Karolinska
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More informationSince the beginning of the prostate-specific antigen (PSA) era in the. Characteristics of Insignificant Clinical T1c Prostate Tumors
2001 Characteristics of Insignificant Clinical T1c Prostate Tumors A Contemporary Analysis Patrick J. Bastian, M.D. 1 Leslie A. Mangold, B.A., M.S. 1 Jonathan I. Epstein, M.D. 2 Alan W. Partin, M.D., Ph.D.
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationPost Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series
Post Radical Prostatectomy Adjuvant Radiation in Patients with Seminal Vesicle Invasion - A Historical Series E. Z. Neulander 1, K. Rubinov 2, W. Mermershtain 2, Z. Wajsman 3 1 Department of Urology, Soroka
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationSupplemental Information
Supplemental Information Prediction of Prostate Cancer Recurrence using Quantitative Phase Imaging Shamira Sridharan 1, Virgilia Macias 2, Krishnarao Tangella 3, André Kajdacsy-Balla 2 and Gabriel Popescu
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationRadical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience
MOLECULAR AND CLINICAL ONCOLOGY 1: 337-342, 2013 Radical prostatectomy as radical cure of prostate cancer in a high risk group: A single-institution experience NOBUKI FURUBAYASHI 1, MOTONOBU NAKAMURA 1,
More informationI M M U L I T E. DPC s Third Generation PSA Assay. The Clinician s Choice for PSA Testing. D P C T e c h n i c a l R e p o r t
D P C T e c h n i c a l R e p o r t I M M U L I T E DPC s Third Generation PSA Assay The Clinician s Choice for PSA Testing Jonathan McDermed, Pharm.D. Marketing Manager, Corporate Marketing DPC s Third
More informationRadiation Therapy After Radical Prostatectomy
Articles ISSN 1537-744X; DOI 10.1100/tsw.2004.93 Radiation Therapy After Radical Ali M. Ziada, M.D. and E. David Crawford, M.D. Division of Urology, University of Colorado, Denver, Colorado E-mails: aziada@mednet3.camed.eun.eg
More informationUse of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence
Cancer Biomarkers 17 (2016) 83 88 83 DOI 10.3233/CBM-160620 IOS Press Use of the cell cycle progression (CCP) score for predicting systemic disease and response to radiation of biochemical recurrence Michael
More informationThe Prostate Specific-Antigen (PSA):
The Prostate Specific-Antigen (PSA): Why it could not detect prostate cancer reliably in the past and How it became a sensitive and specific tumor marker Hans H. Glaettli, dipl. Phys. ETH 0. Summary PSA
More informationAnatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy specimens
& 2005 USCAP, Inc All rights reserved 0893-3952/05 $30.00 www.modernpathology.org Anatomic distribution and pathologic characterization of small-volume prostate cancer (o0.5 ml) in whole-mount prostatectomy
More informationIntroduction. Key Words: high-grade prostatic intraepithelial neoplasia, HGPIN, radical prostatectomy, prostate biopsy, insignificant prostate cancer
Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy Premal Patel, MD, 1 Jasmir G. Nayak, MD, 1,2 Zlatica Biljetina, MD, 4 Bryan Donnelly, MD 3, Kiril
More informationRADICAL PROSTATECTOMY IS ONE
ORIGINAL CONTRIBUTION Risk of Prostate Cancer Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy Stephen J. Freedland, MD Elizabeth B. Humphreys, BS Leslie A. Mangold, MS Mario
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More informationVol. 36, pp , 2008 T1-3N0M0 : T1-3. prostate-specific antigen PSA. 68 Gy National Institutes of Health 10
25 Vol. 36, pp. 25 32, 2008 T1-3N0M0 : 20 2 18 T1-3 N0M0 1990 2006 16 113 59.4-70 Gy 68 Gy 24 prostate-specific antigen PSA 1.2 17.2 6.5 5 91 95 5 100 93 p 0.04 T3 PSA60 ng ml 68 Gy p 0.0008 0.03 0.04
More informationAlthough the test that measures total prostate-specific antigen (PSA) has been
ORIGINAL ARTICLE STEPHEN LIEBERMAN, MD Chief of Urology Kaiser Permanente Northwest Region Clackamas, OR Effective Clinical Practice. 1999;2:266 271 Can Percent Free Prostate-Specific Antigen Reduce the
More informationEvaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in Point of Classification of Bladder Neck Invasion
Jpn J Clin Oncol 2013;43(2)184 188 doi:10.1093/jjco/hys196 Advance Access Publication 5 December 2012 Evaluation of the 7th American Joint Committee on Cancer TNM Staging System for Prostate Cancer in
More informationOne of the most important clinical applications of
PII S0009-9120(99)00099-5 Clinical Biochemistry, Vol. 33, No. 2, 115 123, 2000 Copyright 2000 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/00/$ see front
More informationInvasion of the muscular wall of the seminal vesicles by prostate cancer is generally
PROSTATE CANCER Seminal Vesicle Invasion by Prostate Cancer: Prognostic Significance and Therapeutic Implications Steven R. Potter, MD,* Jonathan I. Epstein, MD,* Alan W. Partin, MD, PhD* *The James Buchanan
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationComparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients
Comparison of external radiation therapy vs radical prostatectomy in lymph node positive prostate cancer patients R Kuefer 1, BG Volkmer 1, M Loeffler 1, RL Shen 2, L Kempf 3, AS Merseburger 4, JE Gschwend
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationReview of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases
Original Article Review of Clinical Manifestations of Biochemicallyadvanced Prostate Cancer Cases Edmund Chiong, 1,2 Alvin Fung Wean Wong, 2 Yiong Huak Chan 3 and Chong Min Chin, 1,2 1 Department of Surgery,
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationPrognostic Value of Surgical Margin Status for Biochemical Recurrence Following Radical Prostatectomy
Original Article Japanese Journal of Clinical Oncology Advance Access published January 17, 2008 Jpn J Clin Oncol doi:10.1093/jjco/hym135 Prognostic Value of Surgical Margin Status for Biochemical Recurrence
More informationIntroduction. Original Article
bs_bs_banner International Journal of Urology (2015) 22, 363 367 doi: 10.1111/iju.12704 Original Article Prostate-specific antigen level, stage or Gleason score: Which is best for predicting outcomes after
More informationUse of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer {
Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer { (2003) 6, 39 44 ß 2003 Nature Publishing Group All rights reserved 1365 7852/03 $25.00 www.nature.com/pcan
More informationProstate Biopsy. Prostate Biopsy. We canʼt go backwards: Screening has helped!
We canʼt go backwards: Screening has helped! Robert E. Donohue M.D. Denver V.A. Medical Center University of Colorado Prostate Biopsy Is cure necessary; when it is possible? Is cure possible; when it is
More informationHormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice
european urology supplements 5 (2006) 362 368 available at www.sciencedirect.com journal homepage: www.europeanurology.com Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice Antonio
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationTHE DILEMMA OF PROSTATE CANcer
ORIGINAL CONTRIBUTION Biological Determinants of Cancer Progression in Men With Prostate Cancer Thomas A. Stamey, MD John E. McNeal, MD Cheryl M. Yemoto Bronislava M. Sigal, PhD Iain M. Johnstone, PhD
More informationProstate Cancer: Is There Standard Treatment? Who has prostate cancer? In this article:
Focus on CME at l Université de Montréal Prostate Cancer: Is There Standard Treatment? Pierre I. Karakiewicz, MD, FRCSC; Paul Perrotte, MD, FRCSC; Fred Saad, MD, FRCSC In this article: 1. Risk factors
More informationMonotherapy with Carbon Ion Radiation for Localized Prostate Cancer
Japanese Journal of Clinical Oncology Advance Access published May 30, 2006 Monotherapy with Carbon Ion Radiation for Localized Prostate Cancer Jun Shimazaki 1, Koichiro Akakura 1, Hiroyoshi Suzuki 1,
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationJAMA. 1998;280:
Original Contributions Biochemical Outcome After Radical Prostatectomy, Radiation Therapy, or Interstitial for Clinically Localized Prostate Cancer Anthony V. D Amico, MD, PhD; Richard Whittington, MD;
More informationHIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED CONFORMAL RADIOTHERAPY IMPROVES THE OUTCOME OF LOCALIZED PROSTATE CANCER
0022-5347/01/1663-0876/0 THE JOURNAL OF UROLOGY Vol. 166, 876 881, September 2001 Copyright 2001 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. HIGH DOSE RADIATION DELIVERED BY INTENSITY MODULATED
More informationORIGINAL ARTICLE. Ja Hyeon Ku 1, Kyung Chul Moon 2, Sung Yong Cho 1, Cheol Kwak 1 and Hyeon Hoe Kim 1
(2011) 13, 248 253 ß 2011 AJA, SIMM & SJTU. All rights reserved 1008-682X/11 $32.00 www.nature.com/aja ORIGINAL ARTICLE Serum prostate-specific antigen value adjusted for non-cancerous prostate tissue
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationjournal of medicine The new england Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy abstract
The new england journal of medicine established in 1812 july 8, 4 vol. 31 no. 2 Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical Prostatectomy Anthony V. D Amico, M.D.,
More informationestimating risk of BCR and risk of aggressive recurrence after RP was assessed using the concordance index, c.
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology PREDICTION OF AGGRESSIVE RECURRENCE AFTER RP SCHROECK et al. BJUI BJU INTERNATIONAL Do nomograms predict aggressive recurrence after radical
More informationChapter 2. Understanding My Diagnosis
Chapter 2. Understanding My Diagnosis With contributions from Nancy L. Brown, Ph.D.,Palo Alto Medical Foundation Research Institute; and Patrick Swift, M.D., Alta Bates Comprehensive Cancer Program o Facts
More informationDepartment of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara , Japan 2
Advances in Urology Volume 2012, Article ID 204215, 7 pages doi:10.1155/2012/204215 Research Article Calculated Tumor Volume Is an Independent Predictor of Biochemical Recurrence in Patients Who Underwent
More informationPSA Screening and Prostate Cancer. Rishi Modh, MD
PSA Screening and Prostate Cancer Rishi Modh, MD ABOUT ME From Tampa Bay Went to Berkeley Prep University of Miami for Undergraduate - 4 years University of Miami for Medical School - 4 Years University
More informationInsignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction
European Urology European Urology 43 (2003) 455 460 Insignificant Prostate Cancer in Radical Prostatectomy Specimen: TimeTrends and Preoperative Prediction Herbert Augustin a,b, Peter G. Hammerer a,c,*,
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationNew Technologies for the Radiotherapy of Prostate Cancer
Prostate Cancer Meyer JL (ed): IMRT, IGRT, SBRT Advances in the Treatment Planning and Delivery of Radiotherapy. Front Radiat Ther Oncol. Basel, Karger, 27, vol. 4, pp 315 337 New Technologies for the
More informationTHE MOST COMMON definitive therapy for the treatment
Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer Michael W. Kattan, Thomas M. Wheeler, and Peter T. Scardino Purpose: Although models exist that place patients
More informationCorrelation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer
ORIGINAL ARTICLE Correlation of Gleason Scores Between Needle-Core Biopsy and Radical Prostatectomy Specimens in Patients with Prostate Cancer Teng-Fu Hsieh, Chao-Hsian Chang, Wen-Chi Chen, Chien-Lung
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationBiochemical progression-free survival in localized prostate cancer patients treated with definitive external beam radiotherapy
Electronic Physician (ISSN: 2008-5842) http://www.ephysician.ir October 2015, Volume: 7, Issue: 6, Pages: 1330-1335, DOI: 10.14661/1330 Biochemical progression-free survival in localized prostate cancer
More informationRadical Prostatectomy versus Intensity Modulated Radiation Therapy in the Management of Localized Prostate Cancer
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 10-19-2009 Radical Prostatectomy versus Intensity Modulated Radiation
More informationProstate-Specific Antigen Testing of Older Men
Prostate-Specific Antigen Testing of Older Men H. Ballentine Carter, Patricia K. Landis, E. Jeffrey Metter, Lee A. Fleisher, Jay D. Pearson Background: Elevated serum prostate-specific antigen (PSA) levels
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationPercentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy
1967 Percentage of Gleason Pattern 4 and 5 Predicts Survival After Radical Prostatectomy Liang Cheng, MD 1,2 Darrell D. Davidson, MD, PhD 1 Haiqun Lin, MD, PhD 3 Michael O. Koch, MD 2 1 Department of Pathology
More informationof Nebraska - Lincoln
University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln U.S. Department of Veterans Affairs Staff Publications U.S. Department of Veterans Affairs 8-2000 Detection, Characterization,
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationEvaluation of pt2 subdivisions in the TNM staging system for prostate cancer
. JOURNAL COMPILATION 2008 BJU INTERNATIONAL Urological Oncology HONG et al. BJUI BJU INTERNATIONAL Evaluation of pt2 subdivisions in the TNM staging system for prostate cancer Sung Kyu Hong, Byung Kyu
More informationProstate Overview Quiz
Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the
More informationPredictive factors of late biochemical recurrence after radical prostatectomy
JJCO Japanese Journal of Clinical Oncology Japanese Journal of Clinical Oncology, 2017, 47(3) 233 238 doi: 10.1093/jjco/hyw181 Advance Access Publication Date: 9 December 2016 Original Article Original
More informationPROSTATE MRI. Dr. Margaret Gallegos Radiologist Santa Fe Imaging
PROSTATE MRI Dr. Margaret Gallegos Radiologist Santa Fe Imaging Topics of today s talk How does prostate MRI work? Definition of multiparametric (mp) MRI Anatomy of prostate gland and MRI imaging Role
More informationChristine M. Fisher, MD
Prostate biopsy upgrading and its implications on treatment modality and outcomes in men treated with radical prostatectomy or permanent seed implantation at UT M.D. Anderson Cancer Center, 2000-2001 By
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationCorrelation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results
ORIGINAL ARTICLE Correlation of Preoperative and Radical Prostatectomy Gleason Score: Examining the Predictors of Upgrade and Downgrade Results Gholamreza Pourmand, Shahram Gooran, Seyed Reza Hossieni,
More informationRadiation dose has been reported to be an important determinant
538 The Relationship of Increasing Radiotherapy Dose to Reduced Distant Metastases and Mortality in Men with Prostate Cancer Rojymon Jacob, M.D. 1 Alexandra L. Hanlon, Ph.D. 2 Eric M. Horwitz, M.D. 1 Benjamin
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationBone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer?
Bone Scanning Who Needs it Among Patients with Newly Diagnosed Prostate Cancer? Megumi Hirobe 1, Atsushi Takahashi 1, Shin-ichi Hisasue 1, Hiroshi Kitamura 1, Yasuharu Kunishima 1, Naoya Masumori 1, Akihiko
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationClinical Case Conference
Clinical Case Conference Intermediate-risk prostate cancer 08/06/2014 Long Pham Clinical Case 64 yo man was found to have elevated PSA of 8.65. TRUS-biopies were negative. Surveillance PSA was 7.2 in 3
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationRadiotherapy for Localized Hormone-refractory Prostate Cancer in Japan
Radiotherapy for Localized Hormone-refractory Prostate Cancer in Japan KATSUMASA NAKAMURA 1, TERUKI TESHIMA 2, YUTAKA TAKAHASHI 2, ATSUSHI IMAI 3, MASAHIKO KOIZUMI 4, NORIO MITSUHASHI 5, YOSHIYUKI SHIOYAMA
More informationA schematic of the rectal probe in contact with the prostate is show in this diagram.
Hello. My name is William Osai. I am a nurse practitioner in the GU Medical Oncology Department at The University of Texas MD Anderson Cancer Center in Houston. Today s presentation is Part 2 of the Overview
More informationA Competing Risk Analysis of Men Age Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer
A Competing Risk Analysis of Men Age 55-74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer Peter C. Albertsen, MD 1 James A. Hanley, PhD 2 Donald F.Gleason, MD, PhD 3
More informationPredictive Models. Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute
Predictive Models Michael W. Kattan, Ph.D. Department of Quantitative Health Sciences and Glickman Urologic and Kidney Institute Treatment for clinically localized prostate cancer Trade off: Substantial
More information